Why do patients with Parkinson's disease fall? A cross-sectional analysis of possible causes of falls. by Schrag, A et al.
ARTICLE OPEN
Why do patients with Parkinson’s disease fall?
A cross-sectional analysis of possible causes of falls
Anette Schrag1, Mahbuba Choudhury1, Diego Kaski1 and David A Gallagher1
BACKGROUND: Falls in Parkinson’s disease (PD) are associated with signiﬁcant injury, disability, hospitalization, and reduced quality
of life.
AIMS: To identify modiﬁable medical causes of falls in a cohort of PD patients.
METHODS: Eighty seven PD patients were interviewed and examined using validated scales assessing motor and nonmotor
aspects of PD, comorbidities and medication use. The frequency of falls in the last month was the primary outcome measure. Falls
were hypothesized to be associated with increasing age, advanced motor severity, particularly axial features (e.g., freezing and
postural instability), and dyskinesia. Nonmotor features hypothesized to be associated with falls included; cognitive impairment,
psychosis, sleep disorders, cardiovascular dysfunction, and ophthalmological and medical comorbidities.
RESULTS: Fallers had longer disease duration, higher Levodopa-equivalent doses, greater ‘On’ time with dyskinesia (all Po0.005),
and higher scores on some Movement Disorder Society-Uniﬁed Parkinson’s Disease Rating Scale items, particularly axial scores.
However, patients with falls did not differ from non-fallers in age or overall motor UPDRS scores. Severity of psychosis, executive
cognitive impairment, autonomic (particularly cardiovascular) dysfunction and sleep disturbances (particularly REM sleep behavioral
disorder) were signiﬁcantly associated with falls (all Po0.005). Fallers more frequently reported use of antidepressants (both
tricyclics and SSRIs) and neuroleptics (Po0.001), but not hypnotics. There was no difference in medical comorbidities,
ophthalmological assessments, fatigue, and apathy scores between the groups. In logistic regression analysis, cardiovascular
dysfunction, antidepressant use, and REM sleep behavioral disorder were signiﬁcantly associated with falls.
CONCLUSIONS: The causes of falls in PD are multifactorial and extend beyond motor impairment and dyskinesia; addressing
these in patients already treated with dopaminergic medications has the potential to improve this important complication of PD.
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INTRODUCTION
Falls in Parkinson’s disease (PD) can lead to injury and hospital
admissions, and result in increased disability, fear of falling, low
mood, and reduced quality of life.1 Despite being recognized as a
difﬁcult management aspect of advanced disease,2 correlation with
disease duration and motor severity is only moderate.3 Although
impairment of postural stability leading to falls is one of the core
features of PD,4 it is likely that other causative factors have an
important role and addressing these may reduce the risk of falling.
Several studies have examined possible ways of predicting falls, with
previous occurrence of falls being one of the main predictors5,6 and
several motor factors including measures assessing postural
stability,7,8 abnormal posture,9 freezing of gait,7,9,10 impairment of
rapid alternating movement,3 and dyskinesia10 identiﬁed. Cognitive
impairment, including measures of global11 and executive
function9,12 have also been associated with falls in PD. Other
nonmotor features including sleep, particularly rapid eye movement
(REM) sleep behavioral disorder (RBD),13,14 autonomic symptoms,8
depression,15 cardiovascular and musculoskeletal comorbidity,12 and
medication use, such as hypnotics and antidepressants,12 have also
been implicated.
Amongst Parkinsonian features, whilst axial motor features such
as posture, postural stability, and freezing of gait have been
associated with falls in PD, the relationship with overall motor
severity is complex6 and there is little available detailed
quantitative information on individual axial and nonaxial items
and their relative potential to cause falls. Also, most studies have
generally focused on motor or nonmotor features independently,
rather than the coexistent and complex inter-relationship of these
factors and how this impacts on falling. Such information would
be useful to understand the mechanisms of falls and guide
management strategies to prevent them.
On the basis of previous studies, we hypothesized that age and
disease severity, prominent axial motor features, and presence of
dyskinesia could directly cause falls in PD. In addition, given the
growing evidence linking falls with nonmotor features, we
assessed autonomic symptoms, particularly cardiovascular func-
tion, general and executive cognitive impairment, sleep distur-
bance, mood, medical comorbidities and medications on the risk
of falls. Finally, it is not known whether reduced vision or visual
perception impacts on the propensity to fall and this was further
investigated in a subset of patients.
MATERIALS AND METHODS
Consecutive patients fulﬁlling UK Brain Bank criteria for PD4 who
participated in a previous study16 were recruited from PD outpatient clinics.
In brief, subjects underwent face-to-face interview, comprising clinical
examination and physician-administered questionnaires and were given
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further questionnaires to complete at home. A subgroup of patients, who
consented to an additional appointment, also had a full ophthalmological
assessment.
The main outcome variable was a question to the patient on the
frequency of falls in the last month. This stratiﬁed the number of falls in
the last month, into four distinct categories; never falling, falling once,
twice and three times, or more. This was chosen as the assessment was
retrospective and recall beyond 1 month is unlikely to be reliable. As the
majority of patients had not had falls, patients were classiﬁed into non-
fallers (never falling) and fallers (falling at least once in the last month).
Relevant other assessments that were included in this study were the
Movement Disorder Society (MDS)-Uniﬁed Parkinson’s Disease Rating Scale
(MDS-UPDRS);17 percentage of time ‘On’, ‘On’ with dyskinesia and ‘Off’
time; Scales for Outcome in Parkinson’s (SCOPA) cognitive scale (SCOPA-
COG),18 SCOPA-autonomic scale (SCOPA-AUT);19 Pittsburgh Sleep Quality
Index (PSQI);20 Epworth Sleepiness Scale;21 International Classiﬁcation of
Sleep Disorders, Revised (ICSD-R) diagnostic criteria for REM sleep
behavioral disorder;22 Parkinson Psychosis Rating Scale;23 Fatigue Severity
Scale;24 Lille Apathy Rating Scale (LARS);25 Hospital Anxiety and Depression
Scale;26 and checklist of a range of comorbidities and medications. A
subgroup of 46 patients also had ophthalmological measures including
logarithm of minimal angle of resolution (logMAR) visual acuity testing,27
Goldmann kinetic perimetry, mean peripheral ﬁeld diameter expressed as
mean radial degrees (MRD),28 retinal photography, descriptive assessment
of cataract presence, location (nuclear, cortical, and subcapsular), and
degree of opacity and 76 had a test for visual object recognition, the
Birmingham Object Recognition Battery.29 Ethical approval was obtained
from the local research ethics committees and informed consent was
obtained from all participants.
Statistical analysis
Statistical analysis was performed using SPSS version 20.0 (SPSS Inc.,
Chicago, IL, USA). Data were visually and statistically assessed for normality
using histograms and the F-test function. Nonparametric data were
expressed as a median and a range. In this analysis, only variables that
were a priori hypothesized to potentially be causative for falls were
compared between fallers and non-fallers. Scales with overlapping content
were avoided. Scale scores were compared using two-sided Mann–
Whitney and categorical variables using χ2-tests, with a signiﬁcance level of
Po0.01 to adjust for multiple comparisons. A forward-stepping logistic
regression model was carried out entering variables associated with falls in
univariate analysis (Po0.01), using subscale scores rather than total scores
where applicable. As the MDS-UPDRS includes items on the majority
of motor and nonmotor aspects of PD and provides more detailed
Table 1. Demographics and motor and nonmotor scale scores between fallers and non-fallers
Median (range) or Number (%) P-valuea
Fallers (n=27) Non-fallers (n=60)
Demographics
Age (years) 70 (58–83) 67.5 (44–86) 0.44
Disease duration (years) 10.8 (0.1–29.1) 4.1 (0–22.8) 0.005
Motor features
MDS-UPDRS part III 36 (12–65) 34 (9–70) 0.24
Dyskinesia (% daytime) 6 (0–75) 0 (0–53) 0.005
‘On’ without dyskinesia (%) 76 (12–100) 100 (7–100) 0.006
‘Off’ time (%) 12 (0–56) 0 (0–54) 0.04
Hoehn and Yahr stage 3 (1–4) 2 (2–5) 0.018
Cognition
SCOPA-COG-total 23 (9–32) 26 (6–39) 0.02
SCOPA-COG-memory 8 (3–13) 9 (1–18) 0.07
SCOPA-COG-attention 4 (2–4) 4 (0–4) 0.24
SCOPA-COG-executive 8 (2–12) 9 (2–12) 0.003
SCOPA-COG-visuospatial 4 (1–5) 4 (0–5) 0.25
Sleep
PSQI 7 (2–19) 5 (1–18) 0.007
Epworth Sleepiness Score 11 (1–20) 5.5 (0–20) 0.04
Presence of RBD 13/27 (48%) 11/60 (18%) 0.004
Psychosis, apathy, fatigue, and depression
PPRS 9 (6–14) 6 (6–15) o0.001
Lille Apathy Rating Scale − 25 (−35 to − 3) −26.5 (−35 to –2) 0.30
Fatigue Severity Scale 4.6 (1.8–7) 4.0 (0–7) 0.06
HADS anxiety 7 (1–15) 4.5 (0–16) 0.06
HADS depression 6 (2–12) 4.5 (0–18) 0.11
Autonomic function
SCOPA-AUT-total 18 (11–36) 10 (3–35) o0.001
SCOPA-AUT-gastrointestinal 4 (1–8) 2 (0–10) o0.004
SCOPA-AUT-urinary 7 (1–15) 4 (0–16) 0.02
SCOPA-AUT-cardiovascular 1 (0–6) 0 (0–3) 0.001
SCOPA-AUT-thermoregulatory 2 (0–11) 1 (0–10) 0.07
SCOPA-AUT-pupillomotor 1 (0–3) 0 (0–3) 0.001
SCOPA-AUT-sexual 3 (0–6) 2 (0–6) 0.14
Abbreviations: HADS, Hospital Anxiety and Depression Scale; MDS-UPDRS, Movement Disorder Society-Uniﬁed Parkinson's Disease Rating Scale; PPRS,
Parkinson Psychosis Rating Scale; PSQI, Pittsburgh Sleep Quality Index; RBD, REM sleep behavioral disorder; SCOPA-AUT, Scales For Outcomes in Parkinson's
Disease Autonomic questionnaire; SCOPA-COG, Scales For Outcomes in Parkinson's Disease Cognition.
aMann–Whitney or χ2-test.
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information on motor aspects, we performed a separate logistic regression
analysis of falls on all MDS-UPDRS items with a signiﬁcance level of
Po0.05.
RESULTS
Twenty-seven of 87 (31%) of participants had experienced falls in
the last month, and of those, 16 had 1, 6 had 2, and 5 had 3 or
more falls. There was no difference in age or sex (Table 1). Those
who reported falls had signiﬁcantly longer disease duration
(median 10.8 vs. 4.1 years, Po0.01), higher Levodopa Equivalent
Unit doses (Po0.01), as well as MDS-UPDRS part I (Nonmotor
Experiences of Daily Living), part II (Motor Experiences of Daily
Living), and part IV (Motor Complications) scores, reﬂecting more
advanced disease. Those who had fallen reported a higher
proportion of the day with dyskinesia and reduced ‘On’ without
dyskinesia episodes compared with non-fallers. However, there
was no signiﬁcant difference between the groups on MDS-UPDRS
part III (Motor Examination).
Fallers performed signiﬁcantly worse on executive cognitive
function tests (SCOPA-COG), psychosis (PPRS) and sleep (PSQI)
scores and presence of RBD was signiﬁcantly higher in fallers.
However, there was no signiﬁcant difference between the two
groups for daytime sleepiness (ESS), fatigue (FSS), apathy (LARS),
anxiety or depression scores (HADS).
Patients with falls had signiﬁcantly more autonomic symptoms
(SCOPA-AUT), particularly greater cardiovascular, pupillomotor,
and gastrointestinal autonomic symptoms were reported.
In terms of dopaminergic or other medication use (Table 2),
fallers were signiﬁcantly more likely to be on antidepressants
(both selective serotonin reuptake inhibitors and tricyclics) and
neuroleptics (Quetiapine only). No signiﬁcant difference was
found for sleep- and other medication or for any comorbidities
(although associations with self-reported depression and psycho-
sis approached signiﬁcance Po0.05).
There was no difference in visual acuity, visual ﬁelds, and any of
the other ophthalmological parameters between fallers and non-
fallers.
Logistic regression analysis
Variables associated in univariate analysis at Po0.01 signiﬁcance
(antidepressant use, neuroleptic use, LEU dose, percent of daytime
in ‘On’ with dyskinesias, percent of daytime in ‘On’ without
dyskinesias, SCOPA-COG-executive function, SCOPA-AUT-Cardio-
vascular, Gastrointestinal, and Pupillomotor scores, PPRS, RBD,
total PSQI score, and duration since diagnosis) were included in a
forward stepwise conditional logistic regression. The logistic
regression model identiﬁed the use of antidepressants, presence
of RBD and cardiovascular autonomic dysfunction as the main
factors associated with falling in the last month (Table 3).
MDS-UPDRS items
Amongst individual MDS-UPDRS items (Figure 1), occurrence of
falls was associated with higher scores in Part I for physician-
assessed items of cognition, hallucinations, anxiety, and depres-
sion and also self-reported light-headedness on standing, fatigue,
and daytime sleepiness. In part II, signiﬁcantly associated self-
reported items included difﬁculties with speech, handwriting,
turning in bed, getting out of bed, freezing, walking and balance,
dressing, saliva and drooling, and eating tasks. In Part III, falls were
associated with difﬁculties with speech and ﬁnger tapping, and
with the predominantly axial features arising from a chair, gait,
posture and postural instability, and in Part IV with the proportion
of time spent ‘On’ with dyskinesia, functional impact of motor
ﬂuctuations and complexity of motor ﬂuctuations.
DISCUSSION
The analysis of potential causes of falls in PD showed that
nonmotor features of PD, particularly RBD, autonomic impairment
and antidepressant medication use, are associated with falls over
and above what is explained by motor severity, disease duration
or dyskinesias in clinic populations of patients with PD.
Motor variables
As expected, those with falls had longer disease duration and
higher levodopa dose, and greater axial symptoms, particularly
stooped posture, postural instability, impaired gait, including
freezing episodes (by history) and inability to rise from a chair. Of
note, we did not ﬁnd any association between falls and the overall
motor severity as assessed on the motor MDS-UPDRS, similar to
what has been reported previously.30 The MDS-UPDRS also
captures tremor and limb akinesia, which are less likely to affect
postural stability and may be more responsive to dopaminergic
medication. In the literature, disease severity measurements have
also not been shown to be a good predictor of falls. However in a
meta-analysis of six prospective studies of falling in PD6 there was
a complex U-shaped relationship, with the risk of falling increasing
as disease severity increased, but remained at this level thereafter
and there was tendency to taper off towards later disease stages.
This may be because those with more advanced disease attempt
to walk less often. In addition, motor ﬂuctuations were associated
with falls, as were freezing episodes by history but not on
examination, suggesting that axial features such as freezing
Table 2. Antiparkinsonian and other medication use
Median (range) or number (%) Signiﬁcance
P-value
Fallers (n=27) Non-fallers
(n=60)
Dopaminergic medication
LEU (mg) 734.3 (1616.7) 330.8 (1700) 0.009
Levodopa 22/27 (81%) 36/60 (60%) 0.05
Dopamine agonist 17/27 (46%) 32/60 (53%) 0.40
MAOB inhibitor 3/27 (11%) 8/60 (13%) 0.77
COMT inhibitor 10/27 (37%) 14/60 (23%) 0.19
Amantadine 7/27 (26%) 4/60 (7%) 0.01
Other medication
Antidepressants 10/27 (37%) 4/60 (7%) o0.001
Neuroleptics 11/27 (41%) 5/60 (8%) o0.001
Sleep medication 2/27 (7%) 3/60 (5%) 0.66
Abbreviation: LEU, Levodopa-equivalent unit.
Table 3. Forward conditional logistic regression for prediction of
fallers
Predictive factor Odds ratio (95% CI) P-value
SCOPA-Autonomic Cardiovascular
subscale
1.935 (1.18–3.16) 0.009
Antidepressant use 6.549 (1.59–26.99) 0.008
Presence of REM sleep behavior
disorder
3.701 (1.16–11.77) 0.03
Abbreviations: CI, conﬁdence interval; SCOPA, Scales for Outcome in
Parkinson’s.
Variables in the equation: Antidepressants, Neuroleptics, Dyskinesia,
SCOPA-COG-executive function, SCOPA-AUT-Cardiovascular, PPRS, RBD,
Total PSQI score, SCOPA-AUT Pupillomotor, SCOPA-AUT Gastrointestinal,
LEU, Duration of diagnosis.
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Figure 1. Odds ratios with 95% conﬁdence intervals for individual Movement Disorder Society (MDS)-Uniﬁed Parkinson’s Disease Rating Scale
(MDS-UPDRS) items signiﬁcantly associated with risk of falling in univariate logistic regression.
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during off-periods contribute to falls but may not be obvious
during the consultation. Dyskinesias were also associated with
increased falling in this study, as previously reported by others.10
Nonmotor variables
Fallers also scored signiﬁcantly worse on scales for a number of
nonmotor features, particularly executive cognitive function,
autonomic symptoms, psychosis, and sleep disturbances. Con-
sistent with this, higher scores on the MDS-UPDRS part I items on
cognition and hallucinations were associated with falls. One of the
strongest associated factors was sleep disturbance (particularly
RBD), which may suggest that these complications of PD arise
from the same pathology as, or alternatively sleep disturbances
independently contribute to, falls and are potentially amenable to
treatment. REM sleep behavior disorder has previously been
linked to falls in PD.31 Several studies also previously found that
falls were signiﬁcantly associated with cognitive impairment
(in particular attention and executive dysfunction),9,11,12,32,33
psychosis34 and cardiovascular dysfunction3,35 and are often
under-recognized.
Potential underlying pathophysiological mechanisms
Although falls are one of the key features of advanced PD,8 and
dopaminergic medications can improve balance impairment in
PD,36 postural instability in PD is comparatively less responsive to
levodopa therapy than limb akinesia or tremor to levodopa
therapy, and it is likely that other pathophysiological mechanisms
are involved in gait disturbance in these patients.37,38 It has been
postulated that noradrenergic deﬁcits such as in the locus
coeruleus37 and cholinergic pathways like the pedunculopontine
have an important role.38 In support of the noradrenergic
hypothesis, a large randomized controlled study using methyl-
phenidate in advanced PD patients, improvements were observed
for gait bradykinesia and freezing of gait.39 In animal models, in
rats, dual cholinergic-dopaminergic lesions were found to result in
falls more frequently than those with either cholinergic or
dopaminergic lesions.40
The ﬁndings of this study conﬁrm from a clinical point of view
that falls are associated with nonmotor features related to non-
dopaminergic dysfunction, i.e., autonomic dysfunction, psychosis,
sleep disorders, and cognitive impairment. All of these are
thought to arise at least in part from deﬁcits in the noradrenergic
and cholinergic pathways with complex interaction of several
neurotransmitter systems.41,42
This association of falls with nondopaminergically determined
nonmotor features raises important considerations for therapy. For
example, recently it has been reported that donepezil reduced
falls in PD patients.43 Whether this is related to cognitive
improvements or direct cholinergic effects on gait and balance
is unknown. It has also been reported that task-speciﬁc cognitive
training improved gait velocity, gait symmetry, and obstacle
negotiation.44–46 In addition, in patients undergoing Deep Brain
Stimulation of the cholinergic pedunculopontine nucleus-
targeted, which has also been implicated in the pathophysiology
of gait disturbance in PD, there was signiﬁcant improvement in
nocturnal sleep and reduction of daytime hypersomnolence.47
Comorbidities
There was no association with other comorbidities as has been
reported previously or with ophthalmological factors. However,
comorbidities and visual dysfunction48 were not common in our
group and this does therefore not exclude that individual patients
with visual or other comorbidities are more prone to falls as a
result of visual impairment, which has been reported in the
literature.12
Medication
Antidepressant and antipsychotic use were associated with falls,
which, as reported previously, may be due to their sedating
effects5,12 Diagnosis and treatment of depression in PD is complex
and mood disorders in the context of neurodegeneration may not
respond in the same way to medication developed for endogen-
ous depression. Evidence for safety and efﬁcacy of individual
antidepressants in PD is limited because of few large double-blind
trials and methodological considerations.49,50 Similarly, the beneﬁt
of psychotic medication in PD has not been established for the
majority of commonly used agents, including quetiapine the
antipsychotic used in patients in this study.50,51 Our study further
emphasizes that psychotropic medication can be associated with
adverse effects, including falls, and caution should be exercised
in using these drugs particularly if efﬁcacy has not been
conﬁrmed in PD.
Limitations of study
Falls information on our patients was recorded retrospectively.
Thus, number of falls may be underestimated, and the study could
only examine associations rather than causality. Prospective
studies need to examine causation of falls and should optimally
be over longer periods of time. We also relied on patient report on
comorbidities and clinical examination and did not exclude
comorbidities such as vascular disorders or vestibular disorders
with further speciﬁc testing. The relative prevalence of these
comorbidities in PD and controls and their contribution to the
occurrence of falls may be area of further research. Nevertheless,
this broad clinical assessment of potential causes of falls highlights
multiple factors associated with falls that can potentially be
addressed in these patients.
CONCLUSION
The causes of falls in PD are multifactorial and extend beyond
progressive motor impairment and dyskinesia. Given the limited
levodopa responsiveness of gait dysfunction and imbalance,
future therapies should also address cognitive and other
nonmotor factors, simultaneously addressing dopaminergic,
cholinergic, and noradrenergic pathways, and prescription of
psychotropic medications should be reviewed critically to avoid
exacerbation of falls.
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